Irvine Scientific introduces BalanCD HEK293 system for large-scale expression of proteins and viral vectors
New product range includes chemically-defined, serum-free media, to increase productivity of viral vectors and recombinant proteins in suspension cultures.
Irvine Scientific has introduced their BalanCD HEK293 System. The system includes a highly versatile series of chemically-defined media designed to increase productivity in a range of applications, rapidly delivering high yields of viral vectors and recombinant proteins.
BalanCD HEK293 System is fully scalable, and supports small to industrial scale batch sizes. Utilizing human embryonic kidney (HEK293) cells, the system supports applications including viral vector production for gene therapy, transient gene expression and recombinant protein production in suspension-adapted HEK293 cells.
Central to the new system’s versatility, scalability, and process efficiency is BalanCD HEK293, a bi-functional medium that supports both growth and transfection in multiple 293 cell lines, which means that there is no need to change media before and after transfection. This is complemented by BalanCD HEK293 Feed, designed to support high density cell growth to maximize production of recombinant proteins. Anti-Clumping Supplement further increases productivity by preventing the natural tendency of HEK293 to aggregate, thereby improving growth.
“Gene therapy is at the forefront of new medical therapies, but the ability to reliably produce viral vectors at industrial scale has been a challenge,” explained Dr Jessie Ni, Chief Scientific Officer at Irvine Scientific. “Our goal is to provide a reproducible solution to attaining high yields of viral vectors using a chemically-defined, suspension-cell-based platform that will help scientists further their ability to provide innovative treatments. Additionally, we designed the BalanCD HEK293 System to provide unmatched flexibility as well as performance to scientists working with 293 cell lines for other applications such as transient protein expression.”
To save time and cost in downstream processing, and to help meet regulatory requirements, BalanCD HEK293 growth and feed media are chemically-defined and animal component-free. Anti-Clumping Supplement is animal-component-free and enzyme-free. All products are manufactured in state-of-the-art cGMP facilities using strict raw material controls. To further facilitate regulatory compliance, Drug Master Files have been filed with the FDA.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance